## Ye-Xiong Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7652864/publications.pdf Version: 2024-02-01



VE-YIONG LI

#	Article	IF	CITATIONS
1	Effect of postmastectomy radiotherapy on pT1-2N1 breast cancer patients with different molecular subtypes. Breast, 2022, 61, 108-117.	2.2	2
2	Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 810580.	2.8	0
3	Long-Term Outcome of Centrally Located Hepatocellular Carcinomas Treated by Radical Resection Combined With Intraoperative Electron Radiotherapy (IOERT). Frontiers in Oncology, 2022, 12, 773301.	2.8	2
4	Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis. BMC Cancer, 2022, 22, 212.	2.6	5
5	Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). Journal of Clinical Oncology, 2022, 40, 1681-1692.	1.6	145
6	Mapping of Level I Axillary Lymph Nodes in Patients with Newly Diagnosed Breast Cancer: Optimal Target Delineation and Treatment Techniques for Breast and Level I Axilla Irradiation. Practical Radiation Oncology, 2022, 12, 487-495.	2.1	1
7	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. Radiation Oncology, 2022, 17, 58.	2.7	4
8	Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. EBioMedicine, 2022, 78, 103945.	6.1	26
9	First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China. International Journal of Radiation Oncology Biology Physics, 2022, 113, 833-844.	0.8	6
10	Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study. Frontiers in Oncology, 2022, 12, 870741.	2.8	4
11	Variability of Target Volumes and Organs at Risk Delineation in Breast Cancer Radiation Therapy: Quality Assurance Results of the Pretrial Benchmark Case for the POTENTIAL Trial. Practical Radiation Oncology, 2022, , .	2.1	2
12	Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma. Annals of Hematology, 2022, 101, 2021-2034.	1.8	2
13	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia, 2021, 35, 130-142.	7.2	70
14	Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia, 2021, 35, 1671-1682.	7.2	14
15	Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial. Journal of Geriatric Oncology, 2021, 12, 572-577.	1.0	6
16	Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Cancer Research and Treatment, 2021, 53, 1156-1165.	3.0	10
17	Automatic segmentation of three clinical target volumes in radiotherapy using lifelong learning. Radiotherapy and Oncology, 2021, 157, 1-7.	0.6	10
18	The prognostic value of MRI-detected extramural vascular invasion (mrEMVI) for rectal cancer patients treated with neoadjuvant therapy: a meta-analysis. European Radiology, 2021, 31, 8827-8837.	4.5	12

#	Article	IF	CITATIONS
19	Stageâ€dependent conditional survival and failure hazard of nonâ€metastatic nasopharyngeal carcinoma after intensityâ€modulated radiation therapy: Clinical implications for treatment strategies and surveillance. Cancer Medicine, 2021, 10, 3613-3621.	2.8	10
20	A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports Journal of Clinical Oncology, 2021, 39, 3510-3510.	1.6	20
21	The status of medical physics in radiotherapy in China. Physica Medica, 2021, 85, 147-157.	0.7	7
22	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
23	A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy. Radiotherapy and Oncology, 2021, 161, 191-197.	0.6	6
24	Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer. Breast, 2021, 58, 72-79.	2.2	6
25	Radiomics Analysis of Fat-Saturated T2-Weighted MRI Sequences for the Prediction of Prognosis in Soft Tissue Sarcoma of the Extremities and Trunk Treated With Neoadjuvant Radiotherapy. Frontiers in Oncology, 2021, 11, 710649.	2.8	8
26	Quality of Life After Partial or Whole-Breast Irradiation in Breast-Conserving Therapy for Low-Risk Breast Cancer: 1-Year Results of a Phase 2 Randomized Controlled Trial. Frontiers in Oncology, 2021, 11, 738318.	2.8	2
27	Phase 2 Study of Adjuvant Radiotherapy Following Narrowâ€Margin Hepatectomy in Patients With HCC. Hepatology, 2021, 74, 2595-2604.	7.3	43
28	Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 447-456.	2.2	1
29	MiRâ€320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Science, 2021, 112, 575-588.	3.9	31
30	Guidelines for radiotherapy of prostate cancer (2020 edition). Precision Radiation Oncology, 2021, 5, 160-182.	1.1	8
31	Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 1532-1543.	2.0	1
32	The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience. Frontiers in Oncology, 2021, 11, 732883.	2.8	3
33	POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial. BMC Cancer, 2021, 21, 1185.	2.6	7
34	Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer. JAMA Network Open, 2021, 4, e2136116.	5.9	2
35	Development and Validation of an MRI-Based Nomogram Model for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy. Frontiers in Oncology, 2021, 11, 784156.	2.8	0
36	Long-term outcomes of moderately hypofractionated radiotherapy (67.5ÂGy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis. Radiation Oncology, 2020, 15, 231.	2.7	4

#	Article	IF	CITATIONS
37	Impact of Magnetic Field on Dose Distribution in MR-Guided Radiotherapy of Head and Neck Cancer. Frontiers in Oncology, 2020, 10, 1739.	2.8	10
38	Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia, 2020, 34, 2576-2591.	7.2	18
39	<p>Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience</p> . Cancer Management and Research, 2020, Volume 12, 11563-11571.	1.9	2
40	Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy. BMC Cancer, 2020, 20, 1132.	2.6	3
41	Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions. BMC Cancer, 2020, 20, 1155.	2.6	6
42	First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Advances, 2020, 4, 3141-3153.	5.2	35
43	Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China. Journal of Clinical Oncology, 2020, 38, 3604-3614.	1.6	58
44	Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes. Cancer, 2020, 126, 3857-3866.	4.1	10
45	Accurate method for evaluating the duration of the entire radiotherapy process. Journal of Applied Clinical Medical Physics, 2020, 21, 252-258.	1.9	10
46	Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis. Frontiers in Oncology, 2020, 10, 571390.	2.8	2
47	Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. Radiation Oncology, 2020, 15, 212.	2.7	4
48	Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer, 2020, 20, 792.	2.6	12
49	Development and external validation of a nomogram to predict four or more positive nodes in breast cancer patients with one to three positive sentinel lymph nodes. Breast, 2020, 53, 143-151.	2.2	9
50	Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of China. Radiotherapy and Oncology, 2020, 148, 243-244.	0.6	6
51	Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment. Biomedicine and Pharmacotherapy, 2020, 128, 110284.	5.6	6
52	Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1030-1039.	0.8	11
53	Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients With Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 277-285.	0.8	33
54	Four-Dimensional Cone-Beam Computed Tomography Image Compression Using Video Encoder for Radiotherapy. Journal of Digital Imaging, 2020, 33, 1292-1300.	2.9	0

#	Article	IF	CITATIONS
55	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. Leukemia, 2020, 34, 2243-2248.	7.2	35
56	Postoperative Radiotherapy in Pathological T2–3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	3.7	23
57	CNN-Based Quality Assurance for Automatic Segmentation of Breast Cancer in Radiotherapy. Frontiers in Oncology, 2020, 10, 524.	2.8	35
58	Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. Annals of Hematology, 2020, 99, 1303-1309.	1.8	1
59	Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy. Frontiers in Oncology, 2020, 10, 605750.	2.8	7
60	Prognosis and Prophylactic Regional Nodal Irradiation in Breast Cancer Patients With the First Isolated Chest Wall Recurrence After Mastectomy. Frontiers in Oncology, 2020, 10, 600525.	2.8	4
61	Riskâ€based, responseâ€adapted therapy for earlyâ€stage extranodal nasalâ€type <scp>NK</scp> /Tâ€cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. American Journal of Hematology, 2020, 95, 1047-1056.	4.1	25
62	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	7.7	427
63	Risk-adapted therapy for advanced-stage natural killer/T-cell lymphoma: An analysis from the China Lymphoma Collaborative Group Study Journal of Clinical Oncology, 2020, 38, e20041-e20041.	1.6	0
64	Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases. Frontiers in Oncology, 2019, 9, 558.	2.8	9
65	Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine,) Tj ETQq1	1 0.71884314	⊦rgBaT /Overio
66	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. Radiotherapy and Oncology, 2019, 140, 159-166.	0.6	16
67	Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy. Theranostics, 2019, 9, 6856-6866.	10.0	27
68	Exploring correlation information for image compression of four-dimensional computed tomography. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1270-1277.	2.0	2
69	Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 352-360.	10.7	258
70	Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leukemia and Lymphoma, 2019, 60, 2669-2678.	1.3	20
71	Moderately hypofractionated breast radiation therapy: is more evidence needed? – Authors' reply. Lancet Oncology, The, 2019, 20, e227.	10.7	0
72	<p>Optimal postoperative adjuvant treatment strategy for HBV-related hepatocellular carcinoma with microvascular invasion: a propensity score analysis</p> . OncoTargets and Therapy, 2019, Volume 12, 1237-1247.	2.0	21

#	Article	IF	CITATIONS
73	Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019) Tj ETQq1 1 0.784	314 rgBT 17.0	/Qyerlock 1
74	Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Cancer Letters, 2019, 449, 1-7.	7.2	12
75	Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. JAMA Network Open, 2019, 2, e190194.	5.9	23
76	A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases. Oncologist, 2019, 24, e914-e920.	3.7	3
77	Comparison of 2 methods for prediction of liver dosimetric indices in hepatocellular cancer IMRT planning. Medical Dosimetry, 2019, 44, e80-e85.	0.9	1
78	Deep Learning Improved Clinical Target Volume Contouring Quality and Efficiency for Postoperative Radiation Therapy in Non-small Cell Lung Cancer. Frontiers in Oncology, 2019, 9, 1192.	2.8	35
79	Cerebral functional abnormalities in patients with nasopharyngeal carcinoma after radiotherapy. Chinese Medical Journal, 2019, 132, 1563-1571.	2.3	8
80	Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases. Journal of Surgical Oncology, 2019, 119, 532-538.	1.7	3
81	A feasibility study on an automated method to generate patientâ€specific dose distributions for radiotherapy using deep learning. Medical Physics, 2019, 46, 56-64.	3.0	124
82	LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. Journal of Cellular Biochemistry, 2019, 120, 5207-5217.	2.6	18
83	Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG). Aging, 2019, 11, 8463-8473.	3.1	11
84	Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy. Cancer Research and Treatment, 2019, 51, 1198-1206.	3.0	10
85	Pretreatment nutritional risk as a prognostic factor in head and neck cancer patients receiving radiotherapy or chemoradiotherapy. Asia Pacific Journal of Clinical Nutrition, 2019, 28, 223-229.	0.4	8
86	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 652-669.	0.8	71
87	Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1026-1033.	0.8	3
88	Evaluation of MLC leaf transmission on IMRT treatment plan quality of patients with advanced lung cancer. Medical Dosimetry, 2018, 43, 313-318.	0.9	7
89	A study of the dosimetric characteristics between different fixed-field IMRT and VMAT in early-stage primary mediastinal B-cell lymphoma. Medical Dosimetry, 2018, 43, 91-99.	0.9	3
90	Riskâ€dependent curability of radiotherapy for elderly patients with earlyâ€stage extranodal nasalâ€type NK/Tâ€cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Medicine, 2018, 7, 5952-5961.	2.8	14

#	Article	IF	CITATIONS
91	PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics, 2018, 8, 5213-5230.	10.0	115
92	Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Management and Research, 2018, Volume 10, 3973-3981.	1.9	20
93	A feasible study on using multiplexed sensitivity-encoding to reduce geometric distortion in diffusion-weighted echo planar imaging. Magnetic Resonance Imaging, 2018, 54, 153-159.	1.8	8
94	Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Advances, 2018, 2, 2369-2377.	5.2	24
95	Fully automatic and robust segmentation of the clinical target volume for radiotherapy of breast cancer using big data and deep learning. Physica Medica, 2018, 50, 13-19.	0.7	121
96	Comparison of Treatment Outcomes With Breast-conserving Surgery Plus Radiotherapy Versus Mastectomy for Patients With Stage I Breast Cancer: A Propensity Score-matched Analysis. Clinical Breast Cancer, 2018, 18, e975-e984.	2.4	21
97	A fast optimization approach for treatment planning of volumetric modulated arc therapy. Radiation Oncology, 2018, 13, 101.	2.7	6
98	Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiotherapy and Oncology, 2018, 129, 3-9.	0.6	30
99	A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer. BMC Cancer, 2018, 18, 803.	2.6	5
100	Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 61-70.	0.8	15
101	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	7.7	426
102	Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypl stage after neoadjuvant chemo-radiotherapy versus de novo stage pl cohort: A propensity score-matched analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 373-381.	2.2	6
103	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group Journal of Clinical Oncology, 2018, 36, 7552-7552.	1.6	0
104	Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer. Gastrointestinal Endoscopy, 2017, 85, 669-674.	1.0	14
105	The Impact of Postoperative Conformal RadiotherapyÂafter Radical Surgery on Survival andÂRecurrence in Pathologic T3N0M0 Esophageal Carcinoma: AÂPropensity Score-Matched Analysis. Journal of Thoracic Oncology, 2017, 12, 1143-1151.	1.1	35
106	Automatic segmentation of the clinical target volume and organs at risk in the planning <scp>CT</scp> for rectal cancer using deep dilated convolutional neural networks. Medical Physics, 2017, 44, 6377-6389.	3.0	241
107	Influence of tumor location on the intensity-modulated radiation therapy plan of helical tomotherapy. Medical Dosimetry, 2017, 42, 334-340.	0.9	2
108	Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate. BMC Cancer, 2017, 17, 182.	2.6	1

#	Article	IF	CITATIONS
109	Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified. Annals of Hematology, 2017, 96, 245-251.	1.8	18
110	Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. JAMA Oncology, 2017, 3, 83.	7.1	64
111	Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance. International Journal of Radiation Oncology Biology Physics, 2017, 97, 50-59.	0.8	19
112	Deep Deconvolutional Neural Network for Target Segmentation of Nasopharyngeal Cancer in Planning Computed Tomography Images. Frontiers in Oncology, 2017, 7, 315.	2.8	157
113	Observation of different tumor motion magnitude within liver and estimate of internal motion margins in postoperative patients with hepatocellular carcinoma. Cancer Management and Research, 2017, Volume 9, 839-848.	1.9	8
114	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. Oncotarget, 2017, 8, 41102-41112.	1.8	10
115	Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy. Oncotarget, 2017, 8, 39727-39735.	1.8	4
116	Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy. Oncotarget, 2017, 8, 92715-92726.	1.8	3
117	GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Medicine (United States), 2016, 95, e2787.	1.0	32
118	Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. Medicine (United States), 2016, 95, e3789.	1.0	17
119	Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring. International Journal of Radiation Oncology Biology Physics, 2016, 96, 379-386.	0.8	6
120	Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. Annals of Hematology, 2016, 95, 1271-1280.	1.8	8
121	Intensity Modulated Radiation Therapy for Early-Stage Primary Gastric Diffuse Large B-Cell Lymphoma: Dosimetric Analysis, Clinical Outcome, and Quality of Life. International Journal of Radiation Oncology Biology Physics, 2016, 95, 712-720.	0.8	8
122	Long-term outcomes of patients with esthesioneuroblastomas: A cohort from a single institution. Oral Oncology, 2016, 53, 48-53.	1.5	31
123	Adjuvant treatment may benefit patients with high-risk upper rectal cancer: A nomogram and recursive partitioning analysis of 547 patients. Oncotarget, 2016, 7, 66160-66169.	1.8	4
124	Nomogram and recursive partitioning analysis to predict overall survival in patients with stage IIB-III thoracic esophageal squamous cell carcinoma after esophagectomy. Oncotarget, 2016, 7, 55211-55221.	1.8	13
125	Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget, 2016, 7, 64233-64243.	1.8	39
126	Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial. Oncotarget, 2016, 7, 25576-25584.	1.8	10

#	Article	IF	CITATIONS
127	Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. Oncotarget, 2016, 7, 46536-46544.	1.8	1
128	Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood, 2015, 126, 1424-1432.	1.4	150
129	Survival benefit with <scp>IMRT</scp> following narrowâ€margin hepatectomy in patients with hepatocellular carcinoma close to major vessels. Liver International, 2015, 35, 2603-2610.	3.9	49
130	Postoperative intensity-modulated radiation therapy provides favorable local control and low toxicities in patients with soft tissue sarcomas in the extremities and trunk wall. OncoTargets and Therapy, 2015, 8, 2843.	2.0	8
131	Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. PLoS ONE, 2015, 10, e0124601.	2.5	3
132	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.8	303
133	Hypofractionated intensity-modulated radiation therapy for prostate cancer confined to the pelvis: analysis of efficacy and late toxicity. Journal of Radiation Oncology, 2015, 4, 95-101.	0.7	3
134	Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma. World Journal of Surgical Oncology, 2015, 13, 190.	1.9	2
135	Mapping Patterns of Ipsilateral Supraclavicular Nodal Metastases in Breast Cancer: Rethinking the Clinical Target Volume for High-risk Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 268-276.	0.8	51
136	Spread patterns of lymph nodes and the value of elective neck irradiation for esthesioneuroblastoma. Radiotherapy and Oncology, 2015, 117, 328-332.	0.6	32
137	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 516-23.	2.2	2
138	Survey on the Use of Radiotherapy to Treat Early Breast Cancer following Breast-conserving Surgery in China. Tumori, 2014, 100, 512-517.	1.1	2
139	Phaseâ€Iâ€study of postoperative radiotherapy combined with capecitabine for gastric cancer. World Journal of Gastroenterology, 2014, 20, 1067.	3.3	10
140	Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract. Leukemia and Lymphoma, 2014, 55, 1832-1837.	1.3	19
141	Clinical Disparity and Favorable Prognoses for Patients With Waldeyer Ring Extranodal Nasal-type NK/T-cell Lymphoma and Diffuse Large B-cell Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 41-46.	1.3	12
142	Immunophenotypic and Clinical Differences Between the Nasal and Extranasal Subtypes of Upper Aerodigestive Tract Natural Killer/T-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 806-813.	0.8	33
143	Changes in postmastectomy radiotherapy targets in breast cancer in China between 1999 and 2008: an epidemiological study. Journal of Radiation Oncology, 2013, 2, 293-301.	0.7	0
144	Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type. Annals of Hematology, 2013, 92, 325-332.	1.8	8

#	Article	IF	CITATIONS
145	Epidemiologic Study of Radiotherapy Use in China in Patients With Breast Cancer Between 1999 and 2008. Clinical Breast Cancer, 2013, 13, 47-52.	2.4	5
146	Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral T-Cell Lymphoma, Not Otherwise Specified. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1051-1056.	0.8	15
147	Epidemiologic study of compliance to postmastectomy radiation therapy guidelines in breast cancer patients in China between 1999 and 2008. Practical Radiation Oncology, 2013, 3, 209-215.	2.1	4
148	High-Dose and Extended-Field Intensity Modulated Radiation Therapy for Early-Stage NK/T-Cell Lymphoma ofÂWaldeyer's Ring: Dosimetric Analysis and Clinical Outcome. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1086-1093.	0.8	51
149	Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy After Doxorubicin-Based Chemotherapy for Primary Mediastinal Large B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1289-1295.	0.8	17
150	Favorable outcome with doxorubicinâ€based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic largeâ€cell lymphoma. European Journal of Haematology, 2013, 90, 195-201.	2.2	18
151	Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood, 2012, 120, 2003-2010.	1.4	93
152	Radiotherapy Alone With Curative Intent in Patients With Stage I Extranodal Nasal-Type NK/T-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1809-1815.	0.8	75
153	Mild Toxicity and Favorable Prognosis of High–Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients With Early-Stage Nasal NK/T-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1115-1121.	0.8	63
154	Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy After Chemotherapy for Early-Stage Hodgkin's Lymphoma With Mediastinal Involvement. International Journal of Radiation Oncology Biology Physics, 2012, 84, 210-216.	0.8	23
155	Postmastectomy chest wall radiotherapy with single low-energy electron beam: An assessment of outcome and prognostic factors. Practical Radiation Oncology, 2012, 2, 106-113.	2.1	3
156	Failure patterns and clinical implications in early stage nasal natural killer/T ell lymphoma treated with primary radiotherapy. Cancer, 2011, 117, 5203-5211.	4.1	58
157	Immunophenotypic characteristics and clinical relevance of CD56+ and CD56â^' extranodal nasal-type natural killer/T-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 417-424.	1.3	25
158	Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiation Oncology, 2010, 5, 73.	2.7	31
159	Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 2905-2912.	7.0	105
160	Diffuse large B ell lymphoma. Cancer, 2009, 115, 4980-4989.	4.1	23
161	Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood, 2009, 114, 4771-4776.	1.4	83
162	Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood, 2008, 112, 3057-3064.	1.4	102

114

#	Article	IF	CITATIONS
163	Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 181-189.	1.6	327

Primary non-hodgkin's lymphoma of the nasal cavity. , 1998, 83, 449-456.